主讲题目：Therapeutic Drug Monitoring using Surface Enhanced Raman Spectroscopy
Abstract: We have for the past ten years been developing and exploring solid Surface Enhanced Raman Spectroscopy (SERS) substrates based on gold or silver coated nanopillars. Recently, we have, with kind support from the Danish Bio Innovation Institute and the European Innovation Council, focused on developing a SERS based platform for therapeutic drug monitoring (TDM). Here, we detect e.g., anti-cancer drugs in patient blood samples, to monitor if the patient is receiving a correct dose within the therapeutic window. The vision is to be able to provide a tool for personalized treatment of critical diseases where correct dosing is essential and where a wrong dose can be lethal or cause severe side effects. We will share our recent findings and the prototype of a complete TDM device, with integrated sample pre-treatment using centrifugal microfluidics.
Biography: Anja Boisen is head of section and professor at department of Health Technology, Technical University of Denmark. She also heads a DNRF and Villum Centre of Excellence named ‘IDUN - Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics’. Her research group focuses on the development and application of nano-sensors, energy harvesting in the body and ingestible devices for sensing, sampling and delivery. Anja is cofounder of companies Cantion, Silmeco BluSense Diagnostics and LightNovo. In 2008 she was awarded the largest research prize in Denmark, the Villum Kann Rasmussen award and in 2012 she was awarded the EliteForsk Award from the Danish ministry of Research, Innovation and Higher Education. In 2020 she was awarded the Order of Dannebrog by her Majesty the Queen of Denmark. In 2021 she was elected fellow of the electrochemical society (ECS) and became MNE 2021 fellow at the annual international conference on Micro and Nano Engineering (MNE).
▲ 下滑查看
Kevin Plaxco教授
美国加州大学圣巴巴拉分校
主讲题目：Molecular vital signs: recent advances in in vivo biosensorsAbstract: The availability of technologies capable of tracking the levels of drugs, metabolites, and biomarkers in real time would revolutionize our understanding of health and our ability to detect and treat disease. Recent years have seen the development of Electrochemical Aptamer-based (EAB) sensors, an in vivo molecular sensing strategy supporting seconds- to sub-second resolution, real-time drug and biomarker measurements. Comprised of an electrode-bound, redox-reporter-modified aptamer that generates a signal via a binding-induced conformational change, EAB sensors do not rely on the chemical transformation of their targets. Thus, unlike, for example, the continuous glucose monitor, EAB sensors are adaptable to a wide range of targets, with more than a dozen drugs and metabolites having been successfully measured in animal models. Here, I highlight both recent technological advances associated with the EAB platform and several advances in pharmacology and physiology enabled by this uniquely high-time-resolution, real-time window into the body’s molecular status. Biography: Kevin Plaxco, a Distinguished Professor at the UC Santa Barbara, holds appointments in the Departments of Chemistry and Biochemistry and of BioEngineering. Prior to joining UCSB in 1998 he received his Ph.D. from Caltech and performed postdoctoral studies at Oxford and the University of Washington. Dr. Plaxco’s research focus is on the physics of biomolecular folding and its engineering applications. A major aim is to harness the speed and specificity of folding in the development of sensors, adaptable surfaces, and smart materials. Dr. Plaxco has co-authored more than 250 papers and two dozen patents on protein folding, protein dynamics, and folding-based sensors and materials. He serves on the scientific boards of a half dozen biotechnology firms, several of which are commercializing technologies developed by his group.
